Siroos Mirzaei
Siroos Mirzaei (born 22 April 1963 in Mashhad) is an Iranian specialist in Nuclear Medicine. He is Head of the Department of Nuclear Medicine of the Wilhelminen Hospital in Vienna.[1] Mirzaei is well known for his scientific work on torture diagnostics with molecular imaging methods.
Siroos Mirzaei | |
---|---|
Born | |
Scientific career | |
Fields | Torture diagnostics, Dementia diagnostics, thyroid diseases, neuroendocrine diseases (NET) |
Institutions | Wilhelminen Hospital in Vienna |
Biography
Mirzaei spent his childhood and adolescence in Mashhad, Iran. When he was 18 years old, he moved to Austria to study medicine at the University of Vienna.[2] He graduated in 1987 and after some experimental jobs such as at the Department of Experimental Anesthesiology of the Vienna General Hospital he moved, in 1989, to Luxembourg to continue his postdoctoral education at the Department of Cardiology and the Department of Infectious Diseases of the Centre Hospitalier de Luxembourg. In 1994 he completed his specialist training in Family Medicine at the Kaiserin Elisabeth Hospital in Vienna and received the Board Certification in General Medicine. In 1994, he changed to Wilhelminen Hospital in Vienna to complete his specialist medical training in Nuclear Medicine which he was certified for in 1998. In the same year, Mirzaei went to Heidelberg, Germany for a research sabbatical at the Department of Endocrinology of the Ruprecht-Karls-University and afterwards he started to work as Staff Physician at the Wilhelminen Hospital Vienna. In 2004, Mirzaei was appointed professor for Nuclear Medicine at the University of Vienna. Since 2007, he has been Head of the Department of Nuclear Medicine at the Wilhelminen Hospital Vienna.[1]
Scientific contribution
Mirzaei has been contributing to the following fields of research:
- Medical evidence on traces of torture with nuclear medicine methods[3][4][5][6][7][8][9]
- Application of PET-CT in oncology[10][11][12][13][14][15][16][17] and dementia diagnostics.[18][19][20][21] Mirzaei and his team are the first center which is applying Cu-64 PSMA in prostate cancer.[22]
- Somatostatin receptor scintigraphy (SRS) and therapy of neuroendocrine diseases (NET) with radionuclides (PRRT)[23][24][25][26][27][28]
- Benign and malign thyroid diseases[11][29][30][31][32]
Honors and awards
- 1996: Elscint Programmier Förderungspreis for the project “Iterative reconstruction of SPECT-Data on an Elscint-Workstation“
- 1999: Mallinckrodt Förderungspreis Nuklearmedizin for the study "Bone Scintigraphy in Screening of Torture Survivors“ published in The Lancet[33]
- 2000: Solidarity Prize of the archdiocese Vienna for the influence of his work on Integration (Hemayat)
- In 2008, Mirzaei himself has introduced a prize called "Young Human Rights Activist Award 2008", which was won by a team from India for its innovative concept on human rights.[34]
Memberships in organisations
Mirzaei's research activity is connected with memberships in various organisations.[2] He was for more than ten years Head of the Education Working Group as well as Board Member of the Austrian Society of Nuclear Medicine, President of the Austrian Nuclear Medicine Physician Union and member of the Executive Committee of the European Board of Nuclear Medicine (UEMS).[35] He also contributes his expertise to the Austrian Society for Radiation Protection, the Society of Nuclear Medicine (SNM), USA and the organisation Doctors without Borders. He is spokesman of the medical division of Amnesty International Austria, expert in the field of torture diagnostics in the Istanbul Protocol[36] and founding member of the organisation HEMAYAT.[37]
Mirzaei is also a member of the Editorial Board of the following scientific journals: Asia Oceania Journal of Nuclear Medicine & Biology,[38] Iranian Journal of Nuclear Medicine[39] and BMC International Health & Human Rights.
Publications
Mirzaei has published over 100 articles in scientific journals.[40]
He is also author of the following two books:
References
- Department of Nuclear Medicine, Wilhelminen Vienna
- CV Mirzaei Siroos
- Zandieh S, Bernt R, Knoll P, Wenzel T, Hittmair K, Haller J, Hergan K, Mirzaei S. Analysis of the Metabolic and Structural Brain Changes in Patients With Torture-Related Post-Traumatic Stress Disorder (TR-PTSD) Using 18F-FDG PET and MRI. Medicine (Baltimore). 2016 Apr;95(15):e3387. doi:10.1097/MD.0000000000003387. PMID 27082610; PMC 4839854.
- Wenzel T, Frewer A, Mirzaei S. The DSM 5 and the Istanbul Protocol: Diagnosis of psychological sequels of torture. Torture. 2015;25(1):51-61. Review. PMID 26021347.
- Mirzaei S, Sonneck-Koenne C, Bruecke T, Aryana K, Knoll P, Zakavi R. Supplementary value of functional imaging in forensic medicine. Torture. 2012;22 Suppl 1:14-20. PMID 22948398.
- Mirzaei S, Knoll P, Köhn H. [Medical aspects of objectifying torture sequels]. Wien Klin Wochenschr. 2004 Aug 31;116(15-16):568-74. German. PMID 15471186.
- Mirzaei S, Knoll P, Keck A, Preitler B, Gutierrez E, Umek H, Köhn H, Pecherstorfer M. Regional cerebral blood flow in patients suffering from post-traumatic stress disorder. Neuropsychobiology. 2001;43(4):260-4. PMID 11340366.
- Wenzel T, Griengl H, Stompe T, Mirzaei S, Kieffer W. Psychological disorders in survivors of torture: exhaustion, impairment and depression. Psychopathology. 2000 Nov-Dec;33(6):292-6. PMID 11060511.
- Mirzaei S, Knoll P, Lipp RW, Wenzel T, Koriska K, Köhn H. Bone scintigraphy in screening of torture survivors. Lancet. 1998 Sep 19;352(9132):949-51. PMID 9752817.
- Capasso E, Durzu S, Piras S, Zandieh S, Knoll P, Haug A, Hacker M, Meleddu C, Mirzaei S. Role of (64)CuCl 2 PET/CT in staging of prostate cancer. Ann Nucl Med. 2015 Jul;29(6):482-8. doi:10.1007/s12149-015-0968-4. Epub 2015 Apr 2. PMID 25833290.
- Zandieh S, Pokieser W, Knoll P, Sonneck-Koenne C, Kudlacek M, Mirzaei S. Oncocytic adenomas of thyroid-mimicking benign or metastatic disease on 18F-FDG-PET scan. Acta Radiol. 2015 Jun;56(6):709-13. doi:10.1177/0284185114537928. Epub 2014 Jun 19. PMID 24948789.
- Ahmadzadehfar H, Rodrigues M, Zakavi R, Knoll P, Mirzaei S. Prognostic significance of the standardized uptake value of pre-therapeutic (18)F-FDG PET in patients with malignant lymphoma. Med Oncol. 2011 Dec;28(4):1570-6. doi:10.1007/s12032-010-9584-2. Epub 2010 Jun 4. PMID 20524086.
- Prosch H, Mirzaei S, Oschatz E, Strasser G, Huber M, Mostbeck G. Case report: Gluteal injection site granulomas: false positive finding on FDG-PET in patients with non-small cell lung cancer. Br J Radiol. 2005 Aug;78(932):758-61. PMID 16046432.
- Fink AM, Holle-Robatsch S, Herzog N, Mirzaei S, Rappersberger K, Lilgenau N, Jurecka W, Steiner A. Positron emission tomography is not useful in detecting metastasis in the sentinel lymph node in patients with primary malignant melanoma stage I and II. Melanoma Res. 2004 Apr;14(2):141-5. PMID 15057045.
- Mirzaei S, Guerchaft M, Bonnier C, Knoll P, Doat M, Braeutigam P. Use of segmented CT transmission map to avoid metal artifacts in PET images by a PET-CT device. BMC Nucl Med. 2005 Jun 14;5(1):3. PMID 15953395; PMC 1164418.
- Mirzaei S, Schratter-Sehn AU, Knoll P, Gerber E, Kumpan W, Schiessel R, Raderer M, Köhn H. [Determination of therapy management in rectal carcinoma by staging with 18-FDG-PET]. Chirurg. 2001 Sep;72(9):1058-61. German. PMID 11594277.
- Mirzaei S, Knoll P, Kohn H. Diagnosis of recurrent astrocytoma with fludeoxyglucose F18 PET scanning. N Engl J Med. 2001 Jun 28;344(26):2030-1. PMID 11430342.
- Dimou E, Booij J, Rodrigues M, Prosch H, Attems J, Knoll P, Zajicek B, Dudczak R, Mostbeck G, Kuntner C, Langer O, Bruecke T, Mirzaei S. Amyloid PET and MRI in Alzheimer's disease and mild cognitive impairment. Curr Alzheimer Res. 2009 Jun;6(3):312-9. Review. PMID 19519314.
- Mirzaei S, Gelpi E, Booij J, Rodrigues M, Neumann I, Zaknun J, Koehn H, Knoll P. New approaches in nuclear medicine for early diagnosis of Alzheimer's disease. Curr Alzheimer Res. 2004 Aug;1(3):219-29. Review. PMID 15975069.
- Mirzaei S, Rodrigues M, Koehn H, Knoll P, Bruecke T. Metabolic impairment of brain metabolism in patients with Lewy body dementia. Eur J Neurol. 2003 Sep;10(5):573-5. PMID 12940841.
- Mirzaei S, Knoll P, Koehn H, Bruecke T. Assessment of diffuse Lewy body disease by 2-[18F]fluoro-2-deoxy-D-glucose positron emission tomography (FDG PET). BMC Nucl Med. 2003 Feb 20;3(1):1. PMID 12625839; PMC 151666.
- B Grubmüller, R P Baum, E Capasso, A Singh, Y Ahmadi, P Knoll, A Floth, S Righi, S Zandieh, C Meleddu, S F Shariat, H C Klingler, S Mirzaei (2016) 64Cu-PSMA-617 PET/CT imaging of prostate adenocarcinoma: First in-human studies Cancer Biotherapy and Radiopharmaceuticals.
- Mirzaei S, Bastati B, Lipp RW, Knoll P, Zojer N, Ludwig H. Additional lesions detected in therapeutic scans with 177Lu-DOTATATE reflect higher affinity of 177Lu-DOTATATE for somatostatin receptors. Oncology. 2011;80(5-6):326-9. doi:10.1159/000329808. Epub 2011 Jul 25. PMID 21791941.
- Rosenberger I, Strauss A, Dobiasch S, Weis C, Szanyi S, Gil-Iceta L, Alonso E, González Esparza M, Gómez-Vallejo V, Szczupak B, Plaza-García S, Mirzaei S, Israel LL, Bianchessi S, Scanziani E, Lellouche JP, Knoll P, Werner J, Felix K, Grenacher L, Reese T, Kreuter J, Jiménez-González M. Targeted diagnostic magnetic nanoparticles for medical imaging of pancreatic cancer. J Control Release. 2015 Sep 28;214:76-84.
- Popov V, Gospavic R, Knoll P, Mirzaei S. Physiologically Based Pharmacokinetic (PBPK) model for biodistribution of radiolabeled peptides in patients with neuroendocrine tumours. Asia Oceania Journal of Nuclear Medicine & Biology.2016.
- Ahmadihosseini H, Abedi J, Ghodsi Rad MA, Zakavi SR, Knoll P, Mirzaei S, Sadeghi R. Diagnostic utility of 99mTc-EDDA-tricine-HYNIC-Tyr3-octreotate SPECT for differentiation of active from inactive pulmonary tuberculosis. Nucl Med Commun. 2014 Dec;35(12):1262-7.
- Mirzaei S, Sohlberg A, Knoll P, Zakavi R, Diemling M. Easy-to-use online software package for internal dose assessment after radionuclide treatment in clinical routine. Clin Nucl Med. 2013 Sep;38(9):686-90. doi:10.1097/RLU.0b013e31828da3db. PMID 23640224.
- Neumann I, Mirzaei S, Birck R, Osinger K, Waldherr R, Köhn HD, Meisl FT. Expression of somatostatin receptors in inflammatory lesions and diagnostic value of somatostatin receptor scintigraphy in patients with ANCA-associated small vessel vasculitis. Rheumatology (Oxford). 2004 Feb;43(2):195-201.
- Zandieh S, Bernt R, Zwerina J, Haller J, Knoll P, Seyeddain O, Mirzaei S. Acoustic Structure Quantification Analysis of the Thyroid in Patients with Diffuse Autoimmune Thyroid Disease. Ultrason Imaging. 2016 Mar;38(2):137-47. doi:10.1177/0161734615580766. Epub 2015 Apr 8. PMID 25855160.
- Schnedl WJ, Mirzaei S, Wallner-Liebmann SJ, Tafeit E, Mangge H, Krause R, Lipp RW. Improvement of Cerebral Hypoperfusion with Levothyroxine Therapy in Hashimoto's Encephalopathy Demonstrated by (99m)Tc-HMPAO-SPECT. Eur Thyroid J. 2013 Jun;2(2):116-9. doi:10.1159/000348523. Epub 2013 Apr 12. PMID 24783049; PMC 3821506.
- Pestitschek M, Sonneck-Koenne C, Zakavi SR, Li S, Knoll P, Mirzaei S. Selenium intake and selenium blood levels: a novel food frequency questionnaire. Wien Klin Wochenschr. 2013 Mar;125(5-6):160-4. doi:10.1007/s00508-013-0334-2. Epub 2013 Mar 19. PMID 23508871.
- Mirzaei S, Krotla G, Knoll P, Koriska K, Köhn H. Possible effect of calcitonin deficiency on bone mass after subtotal thyroidectomy. Acta Med Austriaca. 1999;26(1):29-31. PMID 10230474.
- Mirzaei, S, P Knoll, Rw Lipp, Th Wenzel, K Koriska, and H Köhn. “Bone Scintigraphy in Screening of Torture Survivors.” The Lancet 352, no. 9132 (September 1998): 949–51. doi:10.1016/S0140-6736(98)05049-1.
- Young Human Rights Activist Award 2008, nominations and winner
- European Association of Nuclear Medicine (EBDN), Executive Committee
- Istanbul Protocol, list of experts
- HEMAYAT.org
- Asia Oceania Journal of Nuclear Medicine & Biology, Editorial Board Members
- Iranian Journal of Nuclear Medicine, Editorial Board Members
- "List of Publications, Research Gate". Research Gate. Retrieved 2016-9-24
- Images of Torture, Mandelbaum publisher